Current and Emerging Treatments for Metastatic Renal Cell Carcinoma

Author(s): Carla Cavaliere, Carmine D`Aniello, Chiara Della Pepa, Salvatore Pisconti, Massimiliano Berretta, Gaetano Facchini*

Journal Name: Current Cancer Drug Targets

Volume 18 , Issue 5 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


In the last decades, the treatment of mRCC, metastatic Renal Cell Carcinoma, has become more and more complex due to the approval of a great number of effective systemic treatments that have significantly improved the prognosis of patients suffering from such disease. An additional knowledge of the genetic aberrations and the molecular pathways alterations that underlie RCC, has promoted the development of several novel agents, known as target therapies (TTs). Even though TTs are not curative and all patients eventually progress, an adequate sequencing of these drugs can provide a significant benefit in terms of PFS, Progression Free Survival, and hopefully OS, Overall Survival. To date, there are few data about the optimal sequential use of the TTs hence, in clinical practice, the therapeutic strategy is chosen on the basis of the safety profile of the drug, patients medical history and the pivotal trial results, though such studies often exclude patients with poor performance status and/or severe comorbidities that we routinely see in our clinics. This review aims to provide an overview of the systemic therapies for mRCC both in the newly diagnosed patients and in the subsequent lines of treatment, with a special focus on the last advances about TTs and immunotherapy.

Keywords: Metastatic renal cell cancer, VEGF pathway, mammalian target of rapamycin pathway, first line therapy, immunotherapy, sequence treatment, new pathway, combination therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 08 February, 2017
Page: [468 - 479]
Pages: 12
DOI: 10.2174/1568009617666170209094030
Price: $65

Article Metrics

PDF: 28